Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wells Fargo Maintains Equal-Weight on C4 Therapeutics, Raises Price Target to $8

Author: Benzinga Newsdesk | May 09, 2024 11:58am
Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Equal-Weight and raises the price target from $7 to $8.

Posted In: CCCC